First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)
Lindsey R. Baden(Brigham and Women's Hospital), Dan H. Barouch(Beth Israel Deaconess Medical Center), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Peter Abbink(Beth Israel Deaconess Medical Center), Edith Swann(National Institutes of Health), Mark Wolff(Emmes (United States)), Katherine E. Yanosick(Herzog Hospital), Kathleen H. Krause(Brigham and Women's Hospital), M. Justin Iampietro(Janssen (Netherlands)), Mo Weijtens(Janssen (Netherlands)), Elise Zablowsky(Herzog Hospital), Hayley Loblein(Emmes (United States)), Maria Grazia Pau, Michael S. Seaman(Beth Israel Deaconess Medical Center), Robert Tucker(Brigham and Women's Hospital), James Perry, Jennifer Johnson(Northwestern University), Jaap Goudsmit(Harvard University), Raphael Dolin(Beth Israel Deaconess Medical Center), Alka Patel, Jane A. Kleinjan(Brigham and Women's Hospital), Ann Cheung(Wave Dragon (Denmark)), Lauren Peter(Beth Israel Deaconess Medical Center)
Cited by 168
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
|Science|2020|1.1k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k